Cisatracurium besilate injection and preparation method thereof
By using the combination of benzyl sulfonium stracuronium, tartaric acid and mannitol, the preparation process of the injection solution is simplified, the hydrolysis and high-temperature photosensitive problems of the injection solution under acid-base conditions are solved, and the problem of hydrolysis and high-temperature photosensitive in the injection solution is achieved within a wider range Stability and long validity period reduce production costs.
Patent Information
- Application Number
- CN202411118626.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-12-06
AI Technical Summary
The existing benzenesulfonium cistracurum injection is easy to hydrolyze under acid and alkali conditions, is sensitive to high temperature and light, resulting in poor stability, limiting its storage and transportation conditions, and the existing technology is complex and costly, making it difficult to significantly extend the product. Validity period.
Injection consisting of benzenesulfoncistracurum, tartaric acid and mannitol, tartaric acid as a stabilizer and pH regulator, and mannitol as a stabilizer, mixing and adjusting the pH value to 3.0-4.5 under conditions below 30°C. , simplify the preparation process, avoid nitrogen filling and control the residual oxygen in the headspace to form a stable injection solution.
It significantly delays the formation of degradation products, improves the chemical and physical stability of the injection solution, makes it adapt to more flexible storage conditions, extends the shelf time of the product, reduces production costs, and can be stored at above 25℃ for 6 months. Above, 2-8℃ can be stored for more than 18 months.
Smart Images

Figure BDA0004994370140000011 
Figure BDA0004994370140000051 
Figure BDA0004994370140000061
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a cisatracurium besylate injection and a preparation method thereof. Background Art
[0002] Cisatracurium besylate, chemically named (1R 1'R 2R 2'R)-2,2'(3,11-dioxotridecanylmethylene)bis(1,2,3,4-tetraoxy-6,7-dimethoxy-2-methyl-1-naphthoylisoquinoline)dibenzenesulfonate, is a moderately effective, non-depolarizing skeletal muscle relaxant with an isoquinolinium benzyl ester structure. In the 1990s, Cisatracurium besylate injection was launched on the market as a neuromuscular blocker for clinical use as an auxiliary means of general anesthesia or sedation in the intensive care unit (ICU) to relax skeletal muscles. It has no significant effect on blood pressure and heart rate, and does not cause significant histamine release. It can be used as an auxiliary anesthesia in surgical operations such as tracheal intubation and liver and kidney dysfunction.
[0003] The structural formula of cisatracurium besylate is shown below:
[0004]
[0005] Its structure contains two ester groups, which are sensitive to pH environment. Under certain acid and alkaline conditions, it is easy to hydrolyze, causing the ester bond to break, thereby introducing degradation impurities B, impurity E and impurity H. It also has a quaternary ammonium structure. Quaternary ammonium bases are prone to Hofmann elimination at high temperatures, losing hydrogen on the β carbon and generating corresponding by-products. Its injection is more sensitive to chemical factors and is more likely to produce unnecessary degradation products, which limits the shelf life of the injection. In addition, it is also sensitive to light and heat. Therefore, in the cisatracurium besylate injection The product instructions for the marketed product require that the drug be stored at 2℃-8℃ and away from light to maintain its effectiveness. The instructions mention that it will slowly lose its effectiveness at a rate of about 5% per year under refrigerated conditions (5℃), and at 25℃, the effectiveness loss rate increases to about 5% per month. After moving from the refrigerator to room temperature (25℃) storage conditions, It must be used within 21 days, even if it is put back in the refrigerator. Therefore, the stability of cisatracurium is a problem. As the storage time increases, the content of the injection decreases and the related substances increase. This seriously affects the efficacy of the drug. Therefore, it is necessary to improve the preparation of cisatracurium so that it can be stable to chemical and physical factors during long-term transportation and storage, and suitable for intravenous administration.
[0006] In order to improve the stability of cisatracurium, the common practice in the prior art is to prepare cisatracurium into lyophilized powder, such as CN100531734C, CN105919950A, CN107468658A, CN108703953A, CN107638391B and CN104434822B. These lyophilization processes are time-consuming and complex, and some even introduce liposome preparation technology such as CN106727366A, which will undoubtedly increase production costs.
[0007] Compared with freeze-dried powder injection, water injection has fewer production steps and only requires packaging and sterilization steps. Therefore, the production cost is greatly reduced compared with freeze-dried powder injection. It is also easy to use and reduces the risk of secondary contamination.
[0008] CN107049936B discloses a method for preparing cisatracurium besylate injection, and the preparation process is as follows: taking water for injection, filling it with nitrogen to keep the dissolved oxygen in the water below 1 ppm, then using benzenesulfonic acid solution to adjust the pH value of the water for injection to 3.9-4.1, adding cisatracurium besylate and benzyl alcohol, and mixing until the solution is clear; using benzenesulfonic acid solution to adjust the pH value of the clear solution to 3.0-3.6, and using water for injection to make up the volume to complete the preparation; after the preparation of the drug solution is completed, sterile filtration is performed and then filling is performed, and the headspace residual oxygen content of the injection solution is kept less than 1.0%.
[0009] CN109125259A discloses a method for preparing a preservative-free cisatracurium besylate injection. The main technical scheme is to prepare and keep warm at a low temperature of 2-8°C, and then control the residual oxygen content to less than 5% by vacuuming and nitrogen filling, so as to ensure that the impurities of the product do not exceed the standard within the validity period, but the validity period is not actually extended.
[0010] CN112294756A discloses a cisatracurium besylate injection and a preparation method thereof, which provides a cisatracurium besylate injection containing citric acid and ethanol, wherein the impurity content of the cisatracurium besylate injection increases to more than 5-8% after being stored at room temperature for 6 months.
[0011] Existing technologies can improve product stability to a certain extent, but the production conditions are relatively complex and harsh. Most processes use vacuum extraction and nitrogen filling technology to reduce the amount of residual oxygen in the headspace to ensure its impurity level, and the improved product shelf life is limited.
[0012] Therefore, there is an urgent need to develop a cisatracurium besylate injection with enhanced stability and not overly demanding requirements for daily storage and transportation conditions. Summary of the invention
[0013] The object of the present invention is to overcome the deficiencies in the prior art and provide a cisatracurium besylate injection, which is composed of cisatracurium besylate, tartaric acid, mannitol and water for injection, wherein tartaric acid is a stabilizer and a pH regulator, and mannitol is a stabilizer.
[0014] Preferably, the composition of the cisatracurium besylate injection of the present invention is that per 1000 ml of solution, it contains 2.68 g of cisatracurium besylate, 0.6-3 g of tartaric acid, 1-5 g of mannitol, and the remainder is water for injection, and the pH is 3.0-4.5.
[0015] Preferably, the pH is 3.6-4.2.
[0016] Preferably, the pH of the cisatracurium besylate injection is 3.6, 3.7, 3.8, 3.9, 4.0, 4.1 or 4.2.
[0017] Preferably, the cisatracurium besylate injection of the present invention comprises 2.68 g of cisatracurium besylate, 1.0-1.6 g of tartaric acid, 2-4 g of mannitol, and the remainder is water for injection, with a pH of 3.0-4.5 per 1000 ml of solution.
[0018] Preferably, the composition of the cisatracurium besylate injection of the present invention is that per 1000 ml of solution, it contains 2.68 g of cisatracurium besylate, 1.3 g of tartaric acid, 3 g of mannitol, and the remainder is water for injection, and the pH is 4.0.
[0019] The preferred concentration of tartaric acid is 0.5-5 wt%, preferably 1-2 wt%.
[0020] Preferably, the tartaric acid is L-tartaric acid.
[0021] On the other hand, the present invention provides a method for preparing cisatracurium besylate injection, which comprises the following steps: adding mannitol and tartaric acid to a portion of water for injection at a temperature below 30°C, stirring and mixing, slowly adding atracurium besylate and stirring evenly until it is completely dissolved, adjusting the pH value of the solution to 3.0-4.5 with L-tartaric acid solution, adding water for injection to the fixed volume, stirring and mixing, sterilizing and filtering, and filling and capping to obtain the product.
[0022] In a preferred embodiment, the preparation method of the atracurium besylate injection is as follows: at a temperature below 30°C, 1-5 g of mannitol and 0.6-3 g of tartaric acid are added to 80% water for injection, stirred and mixed, 2.68 g of atracurium besylate is slowly added and stirred evenly until it is completely dissolved, the pH value of the solution is adjusted to 3.0-4.5 with 0.5-5 wt% L-tartaric acid solution, water for injection is added to make up to 1000 ml, stirred and mixed, sterilized and filtered, and filled and capped.
[0023] Another invention is the use of the cisatracurium besylate injection provided by the present invention in the preparation of skeletal muscle relaxant drugs.
[0024] The cisatracurium besylate injection provided by the present invention delays the formation of degradation products. Therefore, the injection provided by the present invention is stable in chemical and physical properties and can adapt to more flexible storage and processing conditions.
[0025] The cisatracurium besylate injection provided by the present invention can be stored at a temperature below 30°C, such as 30°C, 25°C, 15°C, 10°C, and refrigerated conditions such as 2-8°C, and can be stored for at least 18 months at 2-8°C. It can also be stored above room temperature (25°C) and can be stored for more than 6 months.
[0026] Preferably, the storage temperature of the injection of the present invention can be 30°C, or room temperature.
[0027] The experimental results show that when the injection provided by the present invention is stored under the storage conditions, the increase of impurities over time is significantly suppressed.
[0028] In some embodiments, the injection provided by the present invention is stable at 2-8° C. for at least 18 months, at least 12 months.
[0029] The cisatracurium besylate injection provided by the invention has a simple and easy preparation process compared with the cisatracurium besylate injection disclosed in the prior art, and the obtained injection does not need to be filled with nitrogen or control the amount of residual oxygen in the headspace, thereby improving the stability of cisatracurium besylate, extending the shelf life of the product, and saving costs. DETAILED DESCRIPTION
[0030] In order to better understand the technical solution of the present invention, the technical solution of the present invention is further described below in conjunction with specific embodiments. The embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0031] Purchased from ABBVIE INC. (EQ 2mg base / mL), store according to the instructions: 2-8℃ (36-46℉) away from light, do not freeze, once moved from the refrigerator to room temperature (25℃ / 77℉), even if refrigerated, use within 21 days.
[0032] The purchased references were analyzed by physicochemical analysis and are listed in Table 1:
[0033] Table 1
[0034]
[0035] (20mg / 10mL) The formulation analysis is listed in Table 2
[0036] Table 2
[0037] Components Dosage per mL Function Cisatracurium besylate 2.68mg Active ingredients 0.9% Benzyl alcohol 9.0mg preservative Benzenesulfonic acid Moderate pH adjuster (adjust to 3.25-3.65) Water for injection To 1mL Solvents
[0038] The corresponding structures of the impurities are as follows:
[0039]
[0040] Determination method for related substances: Determined by high performance liquid chromatography (Pharmacopoeia of the People's Republic of China 2020 edition, Part II).
[0041] Octadecylsilane bonded silica gel was used as filler; potassium dihydrogen phosphate buffer solution (10.2 g of potassium dihydrogen phosphate was taken, dissolved in about 900 ml of water, the pH value was adjusted to 3.1 with phosphoric acid, and then water was added to 1000 ml), methanol-acetonitrile (75:5:20) was used as mobile phase A; potassium dihydrogen phosphate buffer solution (10.2 g of potassium dihydrogen phosphate was taken, dissolved in about 900 ml of water, the pH value was adjusted to 3.1 with phosphoric acid, and then water was added to 1000 ml), methanol-acetonitrile (50:30:20) was used as mobile phase B, and gradient elution was performed according to the table below; the flow rate was 1.0 ml / min, and the gradient elution was linear; the detection wavelength was 280 nm, and the injection volume was 20 μl.
[0042]
[0043] Example 1: Effects of different stabilizers on the stability of atracurium besylate
[0044] The composition of cisatracurium besylate injection in this embodiment
[0045]
[0046] The preparation method comprises the following steps: adding 3 g of an organic acid stabilizer and 1.3 g of a sugar alcohol stabilizer to 800 ml of water for injection at a temperature below 30°C, stirring and mixing, slowly adding 2.68 g of atracurium besylate and stirring and mixing until the solution is completely dissolved, adjusting the pH value of the solution to 4.0 with a 2 wt % organic acid solution, adding water for injection to 1000 ml, stirring and mixing, performing sterilization filtration through a 0.22 μm filter element, and then filling and capping to obtain a cisatracurium besylate injection with a specification of 20 mg / 10 ml.
[0047] The effect of replacing the organic acid stabilizer and / or the sugar alcohol stabilizer on the stability of cisatracurium besylate was tested according to the formulation in Table 1.
[0048] Table 1
[0049]
[0050]
[0051] Analysis and Conclusion
[0052] This study found that when the stabilizers were L-tartaric acid and mannitol, they could delay the degradation of cisatracurium, while other stabilizers had little effect or accelerated the degradation.
[0053] Example 2: Effect of different stabilizer ratios on the stability of atracurium besylate
[0054]
[0055] Analysis and Conclusion
[0056] This study found that the combination of L-tartaric acid and mannitol can delay the degradation of cisatracurium, while the addition of the two stabilizers alone will accelerate the degradation.
[0057] Example 3: pH sensitivity test of cisatracurium besylate injection
[0058] According to the formula of product 1, cisatracurium besylate injections with different pH values were prepared and pH sensitivity tests were carried out under the conditions of 25°C / 60%RH. The test results are listed in Table 2.
[0059] Table 2
[0060]
[0061]
[0062] Analysis and conclusion:
[0063] With the increase of accelerated storage time, there was no significant change in the properties and pH value of the injection. When the pH was in the range of 3.0-4.5, the related substances increased and the content decreased, but they were all within the standard range. In addition, the content of all samples accelerated for 2 months was within the standard range. Therefore, it can be considered that the injection can be stably stored at 25°C, especially in the pH range of 3.6-4.0, with higher stability.
[0064] Example 4: Headspace gas study of cisatracurium besylate injection
[0065] Product 1 was taken for headspace gas study of cisatracurium besylate injection at 25°C / 60%RH. The test results are listed in Table 3.
[0066] Table 3
[0067]
[0068] Conclusion and Analysis
[0069] As can be seen from Table 3, when the headspace gas of the cisatracurium besylate injection of the present invention is air and the headspace gas is nitrogen, there is no obvious difference in the properties, clarity, content, total impurities and pH of accelerated 2M, and the cisatracurium besylate injection provided by the present invention is not easily oxidized.
[0070] Example 5: Study on the stability of cisatracurium besylate injection
[0071] Product 1 was used for stability study of cisatracurium besylate injection.
[0072] 1. Accelerated testing
[0073] The accelerated conditions are 25°C ± 2°C / 60% RH ± 5% RH.
[0074] Table 4
[0075]
[0076] 2. Long-term stability test
[0077] Long-term conditions are 2-8°C.
[0078] Table 5
[0079]
[0080] Conclusion and Analysis
[0081] It can be seen from the contents of Table 4 and Table 5 that when the cisatracurium besylate injection provided by the present invention is stored under the storage conditions, the increase of impurities over time is significantly suppressed. The cisatracurium besylate injection provided by the present invention can be stored at 2-8°C for at least 18 months. It can also be stored at room temperature (25°C) or above for more than 6 months.
Claims
1. A cisatracurium besylate injection, which is composed of cisatracurium besylate, tartaric acid, mannitol and water for injection, wherein tartaric acid is a stabilizer and a pH regulator, and mannitol is a stabilizer.
2. The injection according to claim 1, wherein the injection comprises 2.68 g of cisatracurium besylate, 0.6-3 g of tartaric acid, 1-5 g of mannitol, and the remainder is water for injection, and the pH value is 3.0-4.
5.
3. The injection according to claim 1, wherein the injection comprises 2.68 g of cisatracurium besylate, 1.0-1.6 g of tartaric acid, 2-4 g of mannitol, and the remainder is water for injection, and the pH value is 3.6-4.
2.
4. The injection according to claim 1, wherein the injection consists of 2.68 g of cisatracurium besylate, 1.3 g of tartaric acid, 3 g of mannitol, and the remainder of water for injection, with a pH of 4.0 per 1000 ml of solution.
5. The injection according to claim 1, wherein the concentration of tartaric acid as a pH regulator is 0.5-5wt%. The injection according to claim 1 , wherein the tartaric acid is L-tartaric acid.
7. The method for preparing the cisatracurium besylate injection according to any one of claims 1 to 6, comprising adding mannitol and tartaric acid to a portion of water for injection at a temperature below 30°C, stirring and mixing, slowly adding atracurium besylate and stirring evenly until it is completely dissolved, adjusting the pH value of the solution to 3.0-4.5 with L-tartaric acid solution, adding water for injection to the fixed volume, stirring and mixing, sterilizing and filtering, and filling and capping.
8. The preparation method according to claim 7, wherein the preparation method of the cisatracurium besylate injection is as follows: at a temperature below 30° C., 1-5 g of mannitol and 0.6-3 g of tartaric acid are added to 80% water for injection, stirred and mixed, 2.68 g of atracurium besylate is slowly added and stirred evenly until it is completely dissolved, the pH value of the solution is adjusted to 3.0-4.5 with 0.5-5 wt % L-tartaric acid solution, water for injection is added to make up to 1000 ml, stirred and mixed, sterilized and filtered, and filled and capped.
9. The cisatracurium besylate injection according to any one of claims 1 to 6, stored at a temperature below 30°C.
10. Use of the cisatracurium besylate injection according to any one of claims 1 to 6 in the preparation of skeletal muscle relaxant drugs.
